Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Volume: 369, Issue: 14, Pages: 1317 - 1326
Published: Oct 2, 2013
Abstract
Background The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. Methods We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including...
Paper Details
Title
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Published Date
Oct 2, 2013
Volume
369
Issue
14
Pages
1317 - 1326
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.